Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4172351 | 0.93 | SNCA (0.44) | SNCAALDH1A1NPC1LMNAMAPT | |
| Bromide SCHEMBL4175689 | 0.82 | HIF1A (0.44) | SNCAALDH1A1LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1539229 | 0.74 | SNCA (0.58) | SNCAALDH1A1NPC1LMNAMAPT | |
| SCHEMBL444673 | 0.73 | TRPA1 (0.48) | ALDH1A1NPC1LMNAMAPTMAPK1 | |
| SCHEMBL8093674 | 0.73 | TP53 (0.50) | ALDH1A1NPC1LMNAMAPTMAPK1 | |
| Bromide SCHEMBL39844 | 0.71 | SNCA (0.73) | SNCAALDH1A1CYP1A2CYP2A6HIF1A | |
| Bromide SCHEMBL2446627 | 0.71 | HIF1A (0.55) | SNCAALDH1A1LMNACYP1A2CYP2A6 | |
| Ethylene SCHEMBL27875997 | 0.69 | TRPA1 (0.44) | ALDH1A1NPC1LMNAMAPTMAPK1 | |
| SCHEMBL9487860 | 0.69 | TRPA1 (0.44) | ALDH1A1NPC1LMNAMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL5972895 | 0.69 | RAB9A (0.44) | SNCAALDH1A1NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-8653142-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2013-09-26 | — | — | US | disclosed |
| US-8420863-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | SNCA 65/4885ALDH1A1 336/4885NPC1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.